News
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...
The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...
Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...
S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.
The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback